Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 58 Results

Title
Intervention Indication Therapeutic Area Year Actions
Cabozantinib for Hepatocellular Carcinoma Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Bintrafusp alfa for locally advanced or metastatic biliary tract cancer – second-line Bintrafusp alfa (M7824; GSK4045154) Biliary tract cancer Gastrointestinal Cancer 2020 View  |  Download
Avelumab for gastric or gastro-oesophageal junction cancer - first line maintenance Avelumab (Bavencio; MSB-0010718C) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2019 View  |  Download
Avelumab for gastric and gastroesophageal junction adenocarcinoma – third line Avelumab (Bavencio; MSB-0010718C) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Avapritinib for unresectable or metastatic gastrointestinal stromal tumours (GIST) who have been treated with at least 3 prior lines of therapy and GIST harbouring the PDGFRA D842V mutation regardless of prior therapy Avapritinib (BLU-285; Ayvakit) Gastrointestinal stromal tumour (GIST) Gastrointestinal Cancer 2019 View  |  Download
Atezolizumab with bevacizumab for patients with resected or ablated hepatocellular carcinoma who are at high risk for disease recurrence Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Atezolizumab in combination with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2019 View  |  Download
Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer - third line Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate) Colorectal cancer Gastrointestinal Cancer , Oncology 2017 View  |  Download
1 2 4 5 6
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications